利索-全球专利检索

  1. 登录
  2. 注册
发明公开
CN106729661A 人尿激肽原酶的新用途及含有人尿激肽原酶的药物组合物 无效 - 驳回

人尿激肽原酶的新用途及含有人尿激肽原酶的药物组合物
摘要：
本发明属于医药领域，具体涉及人尿激肽原酶的新用途及含有人尿激肽原酶的药物组合物。本发明提供的人尿激肽原酶在制备治疗特发性肺纤维化药物中的用途。本发明还提供了治疗特发性肺纤维化的药物组合物，该药物组合物包括人尿激肽原酶和盐酸艾司洛尔，还包括三七总皂苷，所述药物组合物可以显著降低特发性肺纤维化患者的肺系数和血清层粘连蛋白的含量，同时还可以有效的改善特发性肺纤维化患者肺部的损坏组织，延缓特发性肺纤维化的发病进程，大大改善特发性肺纤维化患者的生活质量，提高特发性肺纤维化患者治疗的顺应性，提高治疗效果，为特发性肺纤维化患者提供一种有效的治疗药物，大大的减轻特发性肺纤维化患者的痛苦。
摘要（英）：

The invention belongs to the field of medicines, and in particular relates to a novel application of human urinary kallikein and a medicinal composition containing the human urinary kallikein. The invention specifically provides the application of the human urinary kallikein in preparing medicines for treating idiopathic pulmonary fibrosis. The invention further provides the medicinal composition for treating idiopathic pulmonary fibrosis. The medicinal composition comprises human urinary kallikein and esmolol hydrochloride, and further comprises total panax notoginseng saponins. The medicinal composition can obviously reduce the lung coefficient and content of serum laminin of a patient suffering from idiopathic pulmonary fibrosis, also can effectively improve the injured tissue of the lung of the patient suffering from idiopathic pulmonary fibrosis, so that the attack progress of idiopathic pulmonary fibrosis can be delayed, the living quality of the patient suffering from idiopathic pulmonary fibrosis is greatly improved, the treatment compliance of the patient suffering from idiopathic pulmonary fibrosis is improved, the treatment effect is improved, an effective treatment medicine is provided for the patient suffering from idiopathic pulmonary fibrosis, and the pain of the patient suffering from idiopathic pulmonary fibrosis is greatly alleviated.

0/0